

Jennifer M. Day, PharmD

Coordinator, Emerging Therapeutics Strategy Program
Kaiser Permanente

Paying for Value



Pharmaceutical Evidence Landscape

Evidence



Understanding



*Informed
prescribing*




Challenges to Assessing Value

- Type and amount of evidence available
 - Accelerated approvals and surrogate endpoints
 - Limited or unpublished data
 - Unknowns (e.g., long-term efficacy/safety, optimal dosing or duration)
 - FDA integrated review document?
- Delayed/incomplete post-market confirmatory studies
- Approved indications broader than that studied



Kaiser Permanente's Integrated Model

Physician-Pharmacist Partnership




- Nationally 22,000 physicians
- National Pharmacy Services
 - Outpatient, Inpatient, and Clinic Administered Medication Services
 - Drug Information Services: internal support for clinicians in all care delivery sites
- Maintain goal of evidence-based treatment focusing on quality & safety

Strength of integrated medical and pharmaceutical services

- High level of collaboration between pharmacy and physicians
- Leverage physician expertise nationally
- Fully integrated electronic medical record
- Allows processes for reviewing and monitoring patients

KP Emerging Therapeutics Strategy Program

Proactive strategy development for select new and pipeline emerging therapies



What do we need to be successful?



- Maintain physician-pharmacy partnership
- Promote evidence-based medicine
- Avoid pressure to experiment in clinical practice



- Tighten standards for expedited review pathways
- Judicious use of real-world evidence in drug approval process
- Increase oversight of post-market studies
- Deter abuse of Orphan Drug Act